U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July  30, 2018
INTEGER HOLDINGS CORPORATION
(Exact name of registrant as specified in its charter)

Delaware	 	1-16137	 	16-1531026	
 
(State or Other Jurisdiction of
Incorporation)	 	(Commission File Number)	 	(IRS Employer Identification No.)	
		
5830 Granite Parkway, Suite 1150, Plano, Texas	 	75024	
 
(Address of principal executive offices)	 	(Zip Code)	
Registrant’s telephone number, including area code  (214) 618-5243
                                                             Not Applicable                                                             
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging growth company ☐            
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

Item 7.01.	Regulation FD Disclosure.	
Effective July 30, 2018, senior management of Integer Holdings Corporation (the “Company”) will begin using the materials included in Exhibit 99.1 to this report (the “Historical Financial Information”) in connection with presentations to existing and prospective investors. The Historical Financial Information is incorporated into this Item 7.01 by this reference and will also be available on the Company’s website at www.integer.net, under “Investor Relations – News & Events .” The information found on, or otherwise accessible through, the Company’s website is not incorporated by reference herein.
The information in this Item 7.01 is being furnished, pursuant to Regulation FD, and shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section. The information contained in this report under this Item 7.01 shall not be incorporated by reference into any registration statement or other document filed pursuant to the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
 
Item 9.01.	Financial Statements and Exhibits.	
(d). Exhibits

99.1	 	Historical Financial Information of the Company dated July 30, 2018	

SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated:       July 30, 2018	  	INTEGER HOLDINGS CORPORATION	
			
	  	By:    	  	/s/ Jeremy Friedman                                        	
	  		  	Jeremy Friedman	
	  		  	Executive Vice President and Interim
   Chief Financial Officer	

Exhibit       99.1

 
	
HISTORICAL FINANCIAL INFORMATION	
2017 by Quarter and Total Year - 5 periods
2018 by 1st Quarter - 1 period
GENERAL
 
 	∎	 	Non-GAAP Financial Information	
 
 	∎	 	Discontinued Operations Reporting	
 
 	∎	 	Important Note Regarding Financial Statements	
 
 	∎	 	Assumptions	
HISTORICAL FINANCIAL INFORMATION PRESENTED
Continuing Operations Statements and GAAP to Non-GAAP Reconciliations
 
 	∎	 	GAAP Statements of Continuing Operations Trend	
 
 	∎	 	NON-GAAP Statements of Continuing Operations Trend	
 
 	∎	 	Sales from Continuing Operations Trend	
 
 	∎	 	Income from Continuing Operations Reconciliation Trend	
 
 	∎	 	EBITDA from Continuing Operations Reconciliation Trend	
Bridges To Previously Reported
 
 	∎	 	GAAP Statement of Operations Detail (6 periods)	
 
 	∎	 	Statement of Continuing Operations GAAP to NON-GAAP Reconciliation Detail (6 periods)	
 
 	∎	 	Sales GAAP to Non-GAAP Reconciliation (GAAP & Non-GAAP) (6 periods)	
 
 	∎	 	Net Income GAAP to Non-GAAP Reconciliation (6 periods)	
 
 	∎	 	EBITDA GAAP to Non-GAAP Reconciliation (6 periods)	
 
Page 1 of 39

 
	
NON-GAAP FINANCIAL INFORMATION	
The Company uses non-GAAP financial measures, including the measures provided in this presentation, to describe its operating results as well as the effect of the divestiture of the AS&O business which closed on July 2, 2018. Our management team believes that the presentation of these measures provides useful information to investors and that these measures may assist investors in evaluating the Company’s operations period over period. Investors should consider these non-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.
Non-GAAP measures include the net impact of the Long-term Supply Agreements (“LSA”) entered into between the Company and Viant (formerly MedPlast LLC) as of the closing of the divestiture of the Advanced Surgical and Orthopedic product lines. These long term supply agreements govern the sale of products supplied by Viant to the Company for further resale to customers and by the Company to Viant for further resale to customers.
 
Page 2 of 39

	
DISCONTINUED OPERATIONS REPORTING	
For disposal transactions, a component of an entity that is anticipated to be sold in the future is reported in discontinued operations after it meets the criteria for held-for-sale classification, and if the disposition represents a strategic shift that has (or will have) a major effect on the entity’s operations and financial results. Integer evaluated the quantitative and qualitative factors related to the sale of the AS&O business and concluded that it met the held-for-sale criteria and discontinued operations presentation. The AS&O business financial results are reported within Discontinued Operations in these financial statements.
Interest expense from discontinued operations was computed using the actual weighted average interest rate on the respective debt for the period presented assuming $548 million of cash proceeds from the AS&O sale were used to first redeem all of the Company’s outstanding 9.125% Senior Notes due 2023, second to repay the outstanding balance of the Company’s revolving credit loans outstanding during the period presented, and third, to use the remaining net cash proceeds to prepay the Company’s outstanding Term B loans.
IMPORTANT NOTE REGARDING PRO FORMA FINANCIAL STATEMENTS
These financial statements will not agree to the pro forma financial statements filed by the Company on Form 8-K on July 9, 2018, in connection with the AS&O divestiture as those statements adjust for the pro forma effects in accordance with Article 11 of Regulation S-X. These statements were prepared using the assumptions described herein under the caption Assumptions.
The following financial statements are based on information currently available and have been prepared using certain assumptions and estimates. These unaudited financial statements are intended for informational purposes only, and do not purport to represent what Integer’s financial position and results of operations actually would have been had the AS&O divestiture occurred on the dates indicated, or to project Integer’s financial position or results of operations for any future date or period.
 
Page 3 of 39

	
ASSUMPTIONS	
 
 	∎	 	The following slides present results as if the Integer divestiture of the AS&O business occurred at the beginning of Fiscal Year 2017.	
 
 	∎	 	Income tax provision (benefit) for adjusted amounts were computed using the applicable statutory income tax rates in effect in the respective tax jurisdications during the periods presented. These rates do not reflect our effective tax rate, which include other items and may be significantly different than the rates assumed for purposes of preparing the adjusted financial statements for a variety of factors.	
 
 	∎	 	Adjusted amounts do not reflect the impact of the transition services agreement entered into with Viant to provide certain corporate services (including accounting, payroll, and information technology services) for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant will pay Integer for these services, which payments will vary in amount and length of time as specified in the transition services agreement. As there is no continuing impact on Integer’s results of operations from these transition services, no adjustments were made to the consolidated statements of operations set forth herein.	
 
Page 4 of 39

			
	  	GAAP STATEMENTS OF CONTINUING OPERATIONS
SUMMARY

																													
 	  	2017	 	 	  	2018	
 	  	Q1	  	Q2	  	Q3	 	Q4	 	 	  	FY	 	 	  	Q1	

Sales                                                                                                               	  	  $	266,736	 	  	$	280,916	 	  	$	286,168	 	 	$	302,260	 	 		  	  $	1,136,080	 	 		  	  $	292,426	 	
Cost of sales	  	 	184,708	 	  	 	191,741	 	  	 	196,982	 	 	 	208,639	 	 		  	 	782,070	 	 		  	 	208,894	 	

Gross profit	  	 	82,028	 	  	 	89,175	 	  	 	89,186	 	 	 	93,621	 	 		  	 	354,010	 	 		  	 	83,532	 	
Operating expenses:	  				  				  				 				 		  				 		  				
Selling, general and administrative expenses	  	 	34,794	 	  	 	35,146	 	  	 	35,064	 	 	 	38,069	 	 		  	 	143,073	 	 		  	 	36,429	 	
Research, development and engineering costs	  	 	11,637	 	  	 	11,240	 	  	 	12,227	 	 	 	13,746	 	 		  	 	48,850	 	 		  	 	13,276	 	
Other operating expenses	  	 	11,694	 	  	 	6,727	 	  	 	6,069	 	 	 	11,948	 	 		  	 	36,438	 	 		  	 	3,784	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Total operating expenses	  	 	58,125	 	  	 	53,113	 	  	 	53,360	 	 	 	63,763	 	 		  	 	228,361	 	 		  	 	53,489	 	
Operating income	  	 	23,903	 	  	 	36,062	 	  	 	35,826	 	 	 	29,858	 	 		  	 	125,649	 	 		  	 	30,043	 	
Interest expense	  	 	18,367	 	  	 	15,058	 	  	 	15,808	 	 	 	14,739	 	 		  	 	63,972	 	 		  	 	15,595	 	
(Gain) loss on cost and equity investments, net	  	 	398	 	  	 	4,427	 	  	 	(1,906	) 	 	 	(1,354	) 	 		  	 	1,565	 	 		  	 	(4,970	) 	
Other loss, net	  	 	1,401	 	  	 	6,763	 	  	 	2,490	 	 	 	199	 	 		  	 	10,853	 	 		  	 	960	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Income before taxes	  	 	3,737	 	  	 	9,814	 	  	 	19,434	 	 	 	16,274	 	 		  	 	49,259	 	 		  	 	18,458	 	
Provision (benefit) for income taxes	  	 	789	 	  	 	255	 	  	 	(448	) 	 	 	(38,424	) 	 		  	 	(37,828	) 	 		  	 	5,374	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Income from continuing operations	  	  $	2,948	 	  	$	9,559	 	  	$	19,882	 	 	$	54,698	 	 		  	  $	87,087	 	 		  	  $	13,084	 	

Basic earnings per share	  	  $	0.10	 	  	$	0.31	 	  	$	0.63	 	 	$	1.73	 	 		  	  $	2.77	 	 		  	  $	0.41	 	
Diluted earnings per share	  	  $	0.09	 	  	$	0.30	 	  	$	0.62	 	 	$	1.69	 	 		  	  $	2.72	 	 		  	  $	0.40	 	
 
Page 5 of 39

			
	  	NON-GAAP STATEMENTS OF CONTINUING OPERATIONS
SUMMARY

																													
 	  	2017	 	 	  	2018	
 	  	Q1	  	Q2	  	Q3	  	Q4	 	 	  	FY	 	 	  	Q1	

 	  	 	 	 	  	 	 	 	  	 	
Sales	  	  $	265,256	 	  	$	280,242	 	  	$	284,564	 	  	$	300,692	 	 		  	  $	1,130,754	 	 		  	  $	291,731	 	
Cost of sales	  	 	182,648	 	  	 	190,062	 	  	 	195,042	 	  	 	206,781	 	 		  	 	774,533	 	 		  	 	207,319	 	
	  	 	 	 	 		  	 	 	 	
Gross profit	  	 	82,608	 	  	 	90,180	 	  	 	89,522	 	  	 	93,911	 	 		  	 	356,221	 	 		  	 	84,412	 	
Gross margin	  	 	31%	 	  	 	32%	 	  	 	31%	 	  	 	31%	 	 		  	 	32%	 	 		  	 	29%	 	
Operating expenses:	  				  				  				  				 		  				 		  				
Selling, general and administrative	  	 	28,205	 	  	 	27,981	 	  	 	27,107	 	  	 	30,565	 	 		  	 	113,858	 	 		  	 	29,210	 	
SG&A as a % of sales	  	 	11%	 	  	 	10%	 	  	 	10%	 	  	 	10%	 	 		  	 	43%	 	 		  	 	11%	 	
Research, development and engineering                                                      	  	 	11,501	 	  	 	11,104	 	  	 	12,090	 	  	 	13,610	 	 		  	 	48,305	 	 		  	 	13,237	 	
RD&E as a % of sales	  	 	4%	 	  	 	4%	 	  	 	4%	 	  	 	5%	 	 		  	 	18%	 	 		  	 	5%	 	
Other operating expenses	  	 	-	 	  	 	-	 	  	 	-	 	  	 	-	 	 		  	 	-	 	 		  	 	-	 	
	  	 	 	 	 		  	 	 	 	
Total operating expenses	  	 	39,706	 	  	 	39,085	 	  	 	39,197	 	  	 	44,175	 	 		  	 	162,163	 	 		  	 	42,447	 	
Operating income	  	 	42,902	 	  	 	51,095	 	  	 	50,325	 	  	 	49,736	 	 		  	 	194,058	 	 		  	 	41,965	 	
Operating margin	  	 	16%	 	  	 	18%	 	  	 	18%	 	  	 	17%	 	 		  	 	73%	 	 		  	 	16%	 	
Interest expense	  	 	16,808	 	  	 	14,123	 	  	 	15,030	 	  	 	14,487	 	 		  	 	60,448	 	 		  	 	14,538	 	
Loss on cost and equity investments, net	  	 	-	 	  	 	-	 	  	 	-	 	  	 	-	 	 		  	 	-	 	 		  	 	-	 	
Other (income) loss, net	  	 	1,401	 	  	 	6,763	 	  	 	2,490	 	  	 	199	 	 		  	 	10,853	 	 		  	 	960	 	
	  	 	 	 	 		  	 	 	 	
Income (loss) before taxes	  	 	24,693	 	  	 	30,209	 	  	 	32,805	 	  	 	35,050	 	 		  	 	122,757	 	 		  	 	26,467	 	
Provision for income taxes	  	 	7,333	 	  	 	6,542	 	  	 	3,385	 	  	 	6,384	 	 		  	 	23,644	 	 		  	 	6,048	 	
Effective tax rate	  	 	30%	 	  	 	22%	 	  	 	10%	 	  	 	18%	 	 		  	 	19%	 	 		  	 	23%	 	
	  	 	 	 	 		  	 	 	 	
Income from continuing operations	  	  $	17,360	 	  	$	23,667	 	  	$	29,420	 	  	$	28,666	 	 		  	  $	99,113	 	 		  	  $	20,419	 	

Diluted earnings per share	  	  $	0.55	 	  	$	0.74	 	  	$	0.91	 	  	$	0.89	 	 		  	  $	3.09	 	 		  	  $	0.63	 	
 
Page 6 of 39

			
	  	SALES FROM CONTINUING OPERATIONS
SUMMARY

																													
  	  	2017	 	 	  	2018	
 	  	Q1	  	Q2	  	Q3	  	Q4	 	 	  	FY	 	 	  	Q1	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
GAAP	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	 	 	  	 	 	 	 	 	  	 	 	 	
 	  	 	  	 	  	 	  	 	 	 	  	 	 	 	  	 	
Medical	  				  				  				  				 		  				 		  				
Cardio & Vascular	  	  $	123,484	 	  	$	130,718	 	  	$	137,712	 	  	$	138,917	 	 		  	  $	530,831	 	 		  	  $	136,863	 	
Cardiac & Neuromodulation	  	 	103,755	 	  	 	106,173	 	  	 	101,612	 	  	 	116,735	 	 		  	 	428,275	 	 		  	 	108,910	 	
Advanced Surgical, Orthopedics & Portable Medical	  	 	28,151	 	  	 	28,282	 	  	 	31,715	 	  	 	31,858	 	 		  	 	120,006	 	 		  	 	33,941	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Total Medical	  	 	255,390	 	  	 	265,173	 	  	 	271,039	 	  	 	287,510	 	 		  	 	1,079,112	 	 		  	 	279,714	 	
Non-Medical	  	 	11,346	 	  	 	15,743	 	  	 	15,129	 	  	 	14,750	 	 		  	 	56,968	 	 		  	 	12,712	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Total sales	  	  $	266,736	 	  	$	280,916	 	  	$	286,168	 	  	$	302,260	 	 		  	  $	1,136,080	 	 		  	  $	292,426	 	

NON-GAAP	  	 	 	 	  	 	 	 	  	 	 	 	  	 	 	 	 	 	  	 	 	 	 	 	  	 	 	 	
 	  	 	  	 	  	 	  	 	 	 	  	 	 	 	  	 	
Medical	  				  				  				  				 		  				 		  				
Cardio & Vascular	  	  $	123,486	 	  	$	130,717	 	  	$	137,696	 	  	$	138,905	 	 		  	  $	530,804	 	 		  	  $	136,852	 	
Cardiac & Neuromodulation	  	 	103,753	 	  	 	106,173	 	  	 	101,612	 	  	 	116,735	 	 		  	 	428,273	 	 		  	 	108,910	 	
Advanced Surgical, Orthopedics & Portable Medical	  	 	26,671	 	  	 	27,609	 	  	 	30,127	 	  	 	30,302	 	 		  	 	114,709	 	 		  	 	33,257	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Total Medical	  	 	253,910	 	  	 	264,499	 	  	 	269,435	 	  	 	285,942	 	 		  	 	1,073,786	 	 		  	 	279,019	 	
Non-Medical	  	 	11,346	 	  	 	15,743	 	  	 	15,129	 	  	 	14,750	 	 		  	 	56,968	 	 		  	 	12,712	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Total sales	  	  $	265,256	 	  	$	280,242	 	  	$	284,564	 	  	$	300,692	 	 		  	  $	1,130,754	 	 		  	  $	291,731	 	

Page 7 of 39

			
	  	INCOME FROM CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
SUMMARY	

																													
 	  	2017	 	 	 	  	2018	 	
 	  	      Q1      	 	 	      Q2      	 	 	      Q3      	 	 	      Q4      	 	 	 	  	      FY      	 	 	 	  	      Q1      	 	
 	  	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	  	 	 	
Income from continuing operations (GAAP)	  	$	2,948	 	 	$	9,559	 	 	$	19,882	 	 	$	54,698	 	 		  	$	87,087	 	 		  	$	13,084	 	
Adjustments:	  				 				 				 				 		  				 		  				
Amortization of intangibles	  	 	7,018	 	 	 	7,084	 	 	 	7,103	 	 	 	7,117	 	 		  	 	28,322	 	 		  	 	8,397	 	
Depreciation on held for sale assets	  	 	-    	 	 	 	-    	 	 	 	-    	 	 	 	-    	 	 		  	 	-    	 	 		  	 	-    	 	
IP related litigation (SG&A)	  	 	245	 	 	 	595	 	 	 	1,128	 	 	 	876	 	 		  	 	2,844	 	 		  	 	254	 	
Strategic reorganization and alignment (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	 	 	3,829	 	 		  	 	3,829	 	 		  	 	1,627	 	
Manufacturing alignment to support growth (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	 	 	-    	 	 		  	 	-    	 	 		  	 	369	 	
Consolidation and optimization expenses (OOE)	  	 	1,867	 	 	 	2,028	 	 	 	2,630	 	 	 	3,733	 	 		  	 	10,258	 	 		  	 	455	 	
Acquisition and integration expenses (OOE)	  	 	3,133	 	 	 	2,037	 	 	 	1,106	 	 	 	926	 	 		  	 	7,202	 	 		  	 	-    	 	
Asset dispositions, severance and other (OOE)	  	 	2,928	 	 	 	670	 	 	 	546	 	 	 	356	 	 		  	 	4,500	 	 		  	 	470	 	
(Gain) loss on cost/equity method investments	  	 	259	 	 	 	2,877	 	 	 	(1,239	) 	 	 	(880	) 	 		  	 	1,017	 	 		  	 	(3,926	) 	
Loss on extinguishment of debt	  	 	1,013	 	 	 	608	 	 	 	506	 	 	 	164	 	 		  	 	2,291	 	 		  	 	835	 	
LSA adjustments	  	 	(2,051	) 	 	 	(1,791	) 	 	 	(2,242	) 	 	 	(2,347	) 	 		  	 	(8,431	) 	 		  	 	(2,240	) 	
Tax adjustments	  	 	-    	 	 	 	-    	 	 	 	-    	 	 	 	(39,806	) 	 		  	 	(39,806	) 	 		  	 	1,094	 	
	  	 	 	 	 		  	 	 	 	 		  	 	 	 	
Adjusted income from continuing operations (Non-GAAP)	  	$	17,360	 	 	$	23,667	 	 	$	29,420	 	 	$	28,666	 	 		  	$	99,113	 	 		  	$	20,419	 	

Diluted earnings per share	  	$	0.55	 	 	$	0.74	 	 	$	0.91	 	 	$	0.89	 	 		  	$	3.09	 	 		  	$	0.63	 	
 
Page 8 of 39

			
	  	EBITDA FROM CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
SUMMARY	

																													
 	  	2017	 	 	 	  	2018	 	
EBITDA and Adjusted EBITDA Reconciliation	  	      Q1      	 	 	      Q2      	 	 	      Q3      	 	 	      Q4      	 	 	 	  	      FY      	 	 	 	  	      Q1      	 	
    	  	 	 	 	 	 	 	 	 	 	 	 	 	 	  	 	 	 	 	  	 	 	
Income from continuing operations (GAAP)	  	$	2,948	 	 	$	9,559	 	 	$	19,882	 	 	$	54,698	 	 		  	$	87,087	 	 		  	$	13,084	 	
Adjustments:	  				 				 				 				 		  				 		  				
Interest expense	  	 	18,367	 	 	 	15,058	 	 	 	15,808	 	 	 	14,739	 	 		  	 	63,972	 	 		  	 	15,595	 	
Provision (benefit) for income taxes	  	 	789	 	 	 	255	 	 	 	(448	) 	 	 	(38,424	) 	 		  	 	(37,828	) 	 		  	 	5,374	 	
Depreciation	  	 	9,370	 	 	 	9,358	 	 	 	9,534	 	 	 	9,815	 	 		  	 	38,077	 	 		  	 	9,963	 	
Amortization	  	 	10,083	 	 	 	10,147	 	 	 	10,145	 	 	 	10,193	 	 		  	 	40,568	 	 		  	 	10,653	 	
EBITDA from continuing operations	  	 	41,557	 	 	 	44,377	 	 	 	54,921	 	 	 	51,021	 	 		  	 	191,876	 	 		  	 	54,669	 	
IP related litigation	  	 	377	 	 	 	915	 	 	 	1,735	 	 	 	1,348	 	 		  	 	4,375	 	 		  	 	321	 	
Stock-based compensation (excluding OOE)	  	 	2,173	 	 	 	2,902	 	 	 	2,041	 	 	 	4,167	 	 		  	 	11,283	 	 		  	 	2,979	 	
Strategic reorganization and alignment	  	 	-    	 	 	 	-    	 	 	 	-    	 	 	 	5,891	 	 		  	 	5,891	 	 		  	 	2,054	 	
Manufacturing alignment to support growth	  	 	-    	 	 	 	-    	 	 	 	-    	 	 	 	-    	 	 		  	 	-    	 	 		  	 	513	 	
Consolidation and optimization expenses	  	 	2,347	 	 	 	2,729	 	 	 	2,979	 	 	 	4,880	 	 		  	 	12,803	 	 		  	 	575	 	
Acquisition and integration expenses	  	 	4,820	 	 	 	2,970	 	 	 	2,267	 	 	 	813	 	 		  	 	10,870	 	 		  	 	-    	 	
Asset dispositions, severance and other	  	 	4,527	 	 	 	1,028	 	 	 	823	 	 	 	364	 	 		  	 	6,874	 	 		  	 	642	 	
Non-cash (gain) loss on cost/equity method investments	  	 	398	 	 	 	4,427	 	 	 	(992	) 	 	 	(868	) 	 		  	 	2,965	 	 		  	 	(4,970	) 	
LSA adjustments	  	 	(3,155	) 	 	 	(2,756	) 	 	 	(3,450	) 	 	 	(3,611	) 	 		  	 	(12,972	) 	 		  	 	(2,836	) 	
Adjusted EBITDA from continuing operations (Non-GAAP)	  	$	53,044	 	 	$	56,592	 	 	$	60,324	 	 	$	64,005	 	 		  	$	233,965	 	 		  	$	53,947	 	

Page 9 of 39

			
	  	GAAP STATEMENTS OF OPERATIONS
2017 Q1

 
													
 	 	(a)	 	LESS:	 	 	
 	 	Total	 	Discontinued	 	Continuing	
 	 	Operations	 	Operations	 	Operations	
 	 	 	 	 	 	 	
Sales	 	  $	345,413	 	 	  $	78,677	 	 	  $	266,736	 	
Cost of sales	 	 	254,187	 	 	 	69,479	 	 	 	184,708	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Gross profit	 	 	91,226	 	 	 	9,198	 	 	 	82,028	 	
Operating expenses:	 				 				 				
Selling, general and administrative expenses	 	 	39,499	 	 	 	4,705	 	 	 	34,794	 	
Research, development and engineering costs	 	 	13,411	 	 	 	1,774	 	 	 	11,637	 	
Other operating expenses	 	 	11,771	 	 	 	77	 	 	 	11,694	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Total operating expenses	 	 	64,681	 	 	 	6,556	 	 	 	58,125	 	
Operating income	 	 	26,545	 	 	 	2,642	 	 	 	23,903	 	
Interest expense	 	 	28,893	 	 	 	10,526	 	 	 	18,367	 	
Loss on cost and equity investments, net	 	 	398	 	 	 	-    	 	 	 	398	 	
Other loss, net	 	 	1,449	 	 	 	48	 	 	 	1,401	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Income (loss) before taxes	 	 	(4,195	) 	 	 	(7,932	) 	 	 	3,737	 	
Provision (benefit) for income taxes	 	 	144	 	 	 	(645	) 	 	 	789	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Net loss (income)	 	  $	(4,339	) 	 	  $	(7,287	) 	 	  $	2,948	 	

Basic earnings (loss) per share	 	  $	(0.14	) 	 	 	(0.23	) 	 	  $	0.10	 	
Diluted earnings (loss) per share	 	  $	(0.14	) 	 	 	(0.23	) 	 	  $	0.09	 	
				
Weighted average shares outstanding - Basic	 	 	31,016	 	 	 	31,016	 	 	 	31,016	 	
Weighted average shares outstanding - Diluted	 	 	          31,016	 	 	 	    31,685	 	 	 	        31,685	 	
 
(a)	As previously reported in SEC filings prior to July 2018.    	
 
Page 10 of 39

			
	  	GAAP STATEMENTS OF OPERATIONS
2017 Q2

 
													
 	 	(a)	 	LESS:	 	 	
 	 	Total	 	Discontinued	 	Continuing	
 	 	Operations	 	Operations	 	Operations	
 	 	 	 	 	 	 	
Sales	 	  $	362,719	 	 	  $	81,803	 	 	  $	280,916	 	
Cost of sales	 	 	263,447	 	 	 	71,706	 	 	 	191,741	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Gross profit	 	 	99,272	 	 	 	10,097	 	 	 	89,175	 	
Operating expenses:	 				 				 				
Selling, general and administrative expenses	 	 	39,724	 	 	 	4,578	 	 	 	35,146	 	
Research, development and engineering costs	 	 	12,889	 	 	 	1,649	 	 	 	11,240	 	
Other operating expenses	 	 	6,920	 	 	 	193	 	 	 	6,727	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Total operating expenses	 	 	59,533	 	 	 	6,420	 	 	 	53,113	 	
Operating income	 	 	39,739	 	 	 	3,677	 	 	 	36,062	 	
Interest expense	 	 	25,647	 	 	 	10,589	 	 	 	15,058	 	
Loss on cost and equity investments, net	 	 	4,427	 	 	 	-    	 	 	 	4,427	 	
Other (income) loss, net	 	 	5,549	 	 	 	(1,214	) 	 	 	6,763	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Income (loss) before taxes	 	 	4,116	 	 	 	(5,698	) 	 	 	9,814	 	
Provision for income taxes	 	 	1,126	 	 	 	871	 	 	 	255	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Net income (loss)	 	  $	2,990	 	 	  $	(6,569	) 	 	  $	9,559	 	

Basic earnings (loss) per share	 	  $	0.10	 	 	 	(0.21	) 	 	  $	0.31	 	
Diluted earnings (loss) per share	 	  $	0.09	 	 	 	(0.21	) 	 	  $	0.30	 	
				
Weighted average shares outstanding - Basic	 	 	31,302	 	 	 	31,302	 	 	 	31,302	 	
Weighted average shares outstanding - Diluted	 	 	        31,982	 	 	 	        31,982	 	 	 	        31,982	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 11 of 39

			
	  	GAAP STATEMENTS OF OPERATIONS
2017 Q3

 
													
 	 	(a)	 	LESS:	 	 	
 	 	Total	 	Discontinued	 	Continuing	
 	 	Operations	 	Operations	 	Operations	
 	 	 	 	 	 	 	
Sales	 	  $	363,308	 	 	  $	77,140	 	 	  $	286,168	 	
Cost of sales	 	 	265,073	 	 	 	68,091	 	 	 	196,982	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Gross profit	 	 	98,235	 	 	 	9,049	 	 	 	89,186	 	
Operating expenses:	 				 				 				
Selling, general and administrative expenses	 	 	39,733	 	 	 	4,669	 	 	 	35,064	 	
Research, development and engineering costs	 	 	13,607	 	 	 	1,380	 	 	 	12,227	 	
Other operating expenses	 	 	6,264	 	 	 	195	 	 	 	6,069	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Total operating expenses	 	 	59,604	 	 	 	6,244	 	 	 	53,360	 	
Operating income	 	 	38,631	 	 	 	2,805	 	 	 	35,826	 	
Interest expense	 	 	26,485	 	 	 	10,677	 	 	 	15,808	 	
Gain on cost and equity investments, net	 	 	(1,906	) 	 	 	-    	 	 	 	(1,906	) 	
Other (income) loss, net	 	 	2,062	 	 	 	(428	) 	 	 	2,490	 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Income (loss) before taxes	 	 	11,990	 	 	 	(7,444	) 	 	 	19,434	 	
Benefit for income taxes	 	 	(1,700	) 	 	 	(1,252	) 	 	 	(448	) 	
	 	 	 	 	 	 	 	 	 	 	 	 	
Net income (loss)	 	  $	13,690	 	 	  $	(6,192	) 	 	  $	19,882	 	

Basic earnings (loss) per share	 	  $	0.43	 	 	 	(0.20	) 	 	  $	0.63	 	
Diluted earnings (loss) per share	 	  $	0.43	 	 	 	(0.19	) 	 	  $	0.62	 	
				
Weighted average shares outstanding - Basic	 	 	31,594	 	 	 	31,594	 	 	 	31,594	 	
Weighted average shares outstanding - Diluted	 	 	        32,173	 	 	 	        32,173	 	 	 	        32,173	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 12 of 39

			
	  	GAAP STATEMENTS OF OPERATIONS
2017 Q4

													
 	  	(a)
Total
Operations	 	LESS:
Discontinued
Operations	 	Continuing
Operations	
	  				 				 				
Sales	  	  $	390,481	 	 	  $	        88,221	 	 	  $	    302,260	 	
Cost of sales	  	 	285,663	 	 	 	77,024	 	 	 	208,639	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Gross profit	  	 	104,818	 	 	 	11,197	 	 	 	93,621	 	
Operating expenses:	  				 				 				
Selling, general and administrative expenses	  	 	42,617	 	 	 	4,548	 	 	 	38,069	 	
Research, development and engineering costs	  	 	15,340	 	 	 	1,594	 	 	 	13,746	 	
Other operating expenses	  	 	12,337	 	 	 	389	 	 	 	11,948	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Total operating expenses	  	 	70,294	 	 	 	6,531	 	 	 	63,763	 	
Operating income	  	 	34,524	 	 	 	4,666	 	 	 	29,858	 	
Interest expense	  	 	25,435	 	 	 	10,696	 	 	 	14,739	 	
Gain on cost and equity investments, net	  	 	(1,354	) 	 	 	-    	 	 	 	(1,354	) 	
Other loss, net	  	 	527	 	 	 	328	 	 	 	199	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Income (loss) before taxes	  	 	9,916	 	 	 	(6,358	) 	 	 	16,274	 	
Benefit for income taxes	  	 	(44,422	) 	 	 	(5,998	) 	 	 	(38,424	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Net income (loss)	  	  $	      54,338	 	 	  $	(360	) 	 	  $	54,698	 	

Basic earnings (loss) per share	  	  $	1.71	 	 	 	(0.01	) 	 	  $	1.73	 	
Diluted earnings (loss) per share	  	  $	1.68	 	 	 	(0.01	) 	 	  $	1.69	 	
				
Weighted average shares outstanding - Basic	  	 	31,698	 	 	 	31,698	 	 	 	31,698	 	
Weighted average shares outstanding - Diluted	  	 	32,383	 	 	 	32,383	 	 	 	32,383	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 13 of 39

			
	  	GAAP STATEMENTS OF OPERATIONS
2017 FISCAL YEAR

													
 	  	(a)
Total
Operations	 	LESS:
Discontinued
Operations	 	Continuing
Operations	
	  				 				 				
Sales	  	      $	1,461,921	 	 	  $	        325,841	 	 	  $	    1,136,080	  	
Cost of sales	  	 	1,068,370	 	 	 	286,300	 	 	 	782,070	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Gross profit	  	 	393,551	 	 	 	39,541	 	 	 	354,010	 	
Operating expenses:	  				 				 				
Selling, general and administrative expenses	  	 	161,573	 	 	 	18,500	 	 	 	143,073	 	
Research, development and engineering costs	  	 	55,247	 	 	 	6,397	 	 	 	48,850	 	
Other operating expenses	  	 	37,292	 	 	 	854	 	 	 	36,438	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Total operating expenses	  	 	254,112	 	 	 	25,751	 	 	 	228,361	 	
Operating income	  	 	139,439	 	 	 	13,790	 	 	 	125,649	 	
Interest expense	  	 	106,460	 	 	 	42,488	 	 	 	63,972	 	
Loss on cost and equity investments, net	  	 	1,565	 	 	 	-    	 	 	 	1,565	 	
Other (income) loss, net	  	 	9,587	 	 	 	(1,266	) 	 	 	10,853	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Income (loss) before taxes	  	 	21,827	 	 	 	(27,432	) 	 	 	49,259	 	
Benefit for income taxes	  	 	(44,852	) 	 	 	(7,024	) 	 	 	(37,828	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Net income (loss)	  	  $	66,679	 	 	  $	(20,408	) 	 	  $	87,087	 	

Basic earnings (loss) per share	  	  $	2.12	 	 	 	(0.65	) 	 	  $	2.77	 	
Diluted earnings (loss) per share	  	  $	2.09	 	 	 	(0.64	) 	 	  $	2.72	 	
				
Weighted average shares outstanding - Basic	  	 	31,402	 	 	 	31,402	 	 	 	31,402	 	
Weighted average shares outstanding - Diluted	  	 	31,888	 	 	 	32,056	 	 	 	32,056	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 14 of 39

			
	  	GAAP STATEMENTS OF OPERATIONS
2018 Q1

													
 	  	(a)
Total
Operations	 	LESS:
Discontinued
Operations	 	Continuing
Operations	
	  				 				 				
Sales	  	  $	      381,745	 	 	  $	      89,319	 	 	  $	    292,426	  	
Cost of sales	  	 	285,975	 	 	 	77,081	 	 	 	208,894	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Gross profit	  	 	95,770	 	 	 	12,238	 	 	 	83,532	 	
Operating expenses:	  				 				 				
Selling, general and administrative expenses	  	 	41,238	 	 	 	4,809	 	 	 	36,429	 	
Research, development and engineering costs	  	 	14,538	 	 	 	1,262	 	 	 	13,276	 	
Other operating expenses	  	 	5,277	 	 	 	1,493	 	 	 	3,784	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Total operating expenses	  	 	61,053	 	 	 	7,564	 	 	 	53,489	 	
Operating income	  	 	34,717	 	 	 	4,674	 	 	 	30,043	 	
Interest expense	  	 	26,445	 	 	 	10,850	 	 	 	15,595	 	
Gain on cost and equity investments, net	  	 	(4,970	) 	 	 	-    	 	 	 	(4,970	) 	
Other loss, net	  	 	1,033	 	 	 	73	 	 	 	960	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Income (loss) before taxes	  	 	12,209	 	 	 	(6,249	) 	 	 	18,458	 	
Provision (benefit) for income taxes	  	 	4,091	 	 	 	(1,283	) 	 	 	5,374	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Net income (loss)	  	  $	8,118	 	 	  $	(4,966	) 	 	  $	13,084	 	

Basic earnings (loss) per share	  	  $	0.25	 	 	 	(0.16	) 	 	  $	0.41	 	
Diluted earnings (loss) per share	  	  $	0.25	 	 	 	(0.15	) 	 	  $	0.40	 	
				
Weighted average shares outstanding - Basic	  	 	31,902	 	 	 	31,902	 	 	 	31,902	 	
Weighted average shares outstanding - Diluted	  	 	32,423	 	 	 	32,423	 	 	 	32,423	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 15 of 39

			
	  	STATEMENT OF CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
2017 Q1	

																																															
 	 	GAAP	 	 	 	 	 	 	 	Adjustments	 	 	 	 	 	 	Non-GAAP	
	 				 		 				 				 				 				 				 				 				 				 		 		 				
 	 	Continuing
Operations	 	 	 	 	 	 	 	LSA
adjustment	 	 	Amortization
of intangibles	 	 	IP related
litigation	 	 	Consolidation
and
optimization	 	 	Acquisition
and
integration	 	 	Asset
dispositions,
severance
and other	 	 	Debt /
investment
related
charges	 	 	 	 	 	 	Adjusted
Continuing
Operations	
	 				 		 				 				 				 				 				 				 				 				 		 		 				
Sales	 	$	266,736	 	 		 				 	$	(1,480	) 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 		 		 	$	265,256	  	
Cost of sales	 	 	184,708	 	 		 				 	 	1,675	 	 	 	(3,735	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 		 	 	182,648	 	
	 	 	 	 	 	 	 				 	 	 	 	 	 	 		 	 	 	 	
Gross profit (loss)	 	 	82,028	 	 		 				 	 	(3,155	) 	 	 	3,735	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 		 	 	82,608	 	
Gross margin	 	 	31%	 	 		 				 	 	-1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 		 	 	31%	 	
Operating expenses:	 				 		 				 				 				 				 				 				 				 				 		 		 				
Selling, general and administrative	 	 	34,794	 	 		 				 	 	-	 	 	 	(6,212	) 	 	 	(377	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 		 	 	28,205	 	
SG&A as a % of sales	 	 	13%	 	 		 				 	 	0%	 	 	 	-2%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 		 	 	11%	 	
Research, development and engineering	 	 	11,637	 	 		 				 	 	-	 	 	 	(136	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 		 	 	11,501	 	
RD&E as a % of sales	 	 	4%	 	 		 				 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 		 	 	4%	 	
Other operating expenses	 	 	11,694	 	 		 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	(2,347	) 	 	 	(4,820	) 	 	 	(4,527	) 	 	 	-	 	 		 		 	 	-	 	
	 	 	 	 	 	 	 				 	 	 	 	 	 	 		 	 	 	 	
Total operating expenses	 	 	58,125	 	 		 				 	 	-	 	 	 	(6,348	) 	 	 	(377	) 	 	 	(2,347	) 	 	 	(4,820	) 	 	 	(4,527	) 	 	 	-	 	 		 		 	 	39,706	 	
Operating income (loss)	 	 	23,903	 	 		 				 	 	(3,155	) 	 	 	10,083	 	 	 	377	 	 	 	2,347	 	 	 	4,820	 	 	 	4,527	 	 	 	-	 	 		 		 	 	42,902	 	
Operating margin	 	 	9%	 	 		 				 	 	-1%	 	 	 	4%	 	 	 	0%	 	 	 	1%	 	 	 	2%	 	 	 	2%	 	 	 	0%	 	 		 		 	 	16%	 	
Interest expense	 	 	18,367	 	 		 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(1,559	) 	 		 		 	 	16,808	 	
Loss (gain) on cost and equity investments, net	 	 	398	 	 		 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(398	) 	 		 		 	 	-	 	
Other loss, net	 	 	1,401	 	 		 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 		 	 	1,401	 	
	 	 	 	 	 	 	 				 	 	 	 	 	 	 		 	 	 	 	
Income (loss) before taxes	 	 	3,737	 	 		 				 	 	(3,155	) 	 	 	10,083	 	 	 	377	 	 	 	2,347	 	 	 	4,820	 	 	 	4,527	 	 	 	1,957	 	 		 		 	 	24,693	 	
Provision (benefit) for income taxes	 	 	789	 	 		 				 	 	(1,104	) 	 	 	3,065	 	 	 	132	 	 	 	480	 	 	 	1,687	 	 	 	1,599	 	 	 	685	 	 		 		 	 	7,333	 	
Effective tax rate	 	 	21%	 	 		 				 	 	35%	 	 	 	30%	 	 	 	35%	 	 	 	20%	 	 	 	35%	 	 	 	35%	 	 	 	35%	 	 		 		 	 	30%	 	
	 	 	 	 	 	 	 				 	 	 	 	 	 	 		 	 	 	 	
Net income (loss)	 	$	2,948	 	 		 				 	$	(2,051	) 	 	$	7,018	 	 	$	245	 	 	$	1,867	 	 	$	3,133	 	 	$	2,928	 	 	$	1,272	 	 		 		 	$	17,360	 	

Diluted earnings (loss) per share	 	$	0.09	 	 		 				 	$	(0.06	) 	 	$	0.22	 	 	$	0.01	 	 	$	0.06	 	 	$	0.10	 	 	$	0.09	 	 	$	0.04	 	 		 		 	$	0.55	 	
														
Weighted average shares - Diluted	 	 	31,685	 	 		 				 	 	31,685	 	 	 	31,685	 	 	 	31,685	 	 	 	31,685	 	 	 	31,685	 	 	 	31,685	 	 	 	31,685	 	 		 		 	 	31,685	 	
 
Page 16 of 39

			
	  	STATEMENT OF CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
2017 Q2	

 	 	GAAP	 	 	 	 	 	Adjustments	 	 	 	 	 	Non-GAAP	 	
 	 	Continuing
Operations	 	 	 	 	 	LSA
adjustment	 	 	Amortization
of intangibles	 	 	IP related
litigation	 	 	Consolidation
and
optimization	 	 	Acquisition
and
integration	 	 	Asset
dispositions,
severance
and other	 	 	 
Debt /
investment
related
charges	 	 	 	 	 	Adjusted
Continuing
Operations	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Sales	 	$	280,916	 	 				 	$	(674	) 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 				 	$	280,242	 	
Cost of sales	 	 	191,741	 	 	 		 	 	 	2,082	 	 	 	(3,761	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 				 	 	190,062	 	
Gross profit (loss)	 	 	89,175	 	 				 	 	(2,756	) 	 	 	3,761	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 				 	 	90,180	 	
Gross margin	 	 	32%	 	 				 	 	-1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 				 	 	32%	 	
Operating expenses:	 				 				 				 				 				 				 				 				 				 				 				
Selling, general and administrative	 	 	35,146	 	 				 	 	-	 	 	 	(6,250	) 	 	 	(915	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 		 	 	 	27,981	 	
SG&A as a % of sales	 	 	13%	 	 				 	 	0%	 	 	 	-2%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 				 	 	10%	 	
Research, development and engineering	 	 	11,240	 	 				 	 	-	 	 	 	(136	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 				 	 	11,104	 	
RD&E as a % of sales	 	 	4%	 	 				 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 				 	 	4%	 	
Other operating expenses	 	 	6,727	 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	(2,729	) 	 	 	(2,970	) 	 	 	(1,028	) 	 	 	-	 	 				 	 	-	 	
Total operating expenses	 	 	53,113	 	 				 	 	-	 	 	 	(6,386	) 	 	 	(915	) 	 	 	(2,729	) 	 	 	(2,970	) 	 	 	(1,028	) 	 	 	-	 	 				 	 	39,085	 	
Operating income (loss)	 	 	36,062	 	 				 	 	(2,756	) 	 	 	10,147	 	 	 	915	 	 	 	2,729	 	 	 	2,970	 	 	 	1,028	 	 	 	-	 	 				 	 	51,095	 	
Operating margin	 	 	13%	 	 				 	 	-1%	 	 	 	4%	 	 	 	0%	 	 	 	1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 				 	 	18%	 	
Interest expense	 	 	15,058	 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(935	) 	 				 	 	14,123	 	
Loss (gain) on cost and equity investments, net	 	 	4,427	 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(4,427	) 	 				 	 	-	 	
Other loss, net	 	 	6,763	 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 				 	 	6,763	 	
Income (loss) before taxes	 	 	9,814	 	 				 	 	(2,756	) 	 	 	10,147	 	 	 	915	 	 	 	2,729	 	 	 	2,970	 	 	 	1,028	 	 	 	5,362	 	 				 	 	30,209	 	
Provision (benefit) for income taxes	 	 	255	 	 				 	 	(965	) 	 	 	3,063	 	 	 	320	 	 	 	701	 	 	 	933	 	 	 	358	 	 	 	1,877	 	 				 	 	6,542	 	
Effective tax rate	 	 	3%	 	 				 	 	35%	 	 	 	30%	 	 	 	35%	 	 	 	26%	 	 	 	31%	 	 	 	35%	 	 	 	35%	 	 				 	 	22%	 	
Net income (loss)	 	$	9,559	 	 				 	$	(1,791	) 	 	$	7,084	 	 	$	595	 	 	$	2,028	 	 	$	2,037	 	 	$	670	 	 	$	3,485	 	 				 	$	23,667	 	

Diluted earnings (loss) per share	 	$	0.30	 	 				 	$	(0.06	) 	 	$	0.22	 	 	$	0.02	 	 	$	0.06	 	 	$	0.06	 	 	$	0.02	 	 	$	0.11	 	 				 	$	0.74	 	
												
Weighted average shares - Diluted	 	 	31,982	 	 				 	 	31,982	 	 	 	31,982	 	 	 	31,982	 	 	 	31,982	 	 	 	31,982	 	 	 	31,982	 	 	 	31,982	 	 				 	 	31,982	 	
 
Page 17 of 39

			
	  	STATEMENT OF CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
2017 Q3	

																																											
 	 	GAAP	 	 	 	 	 	Adjustments	 	 	 	 	Non-GAAP	 	
 	 	Continuing
Operations	 	 	 	 	 	LSA
adjustment	 	 	Amortization
of intangibles	 	 	IP related
litigation	 	 	Consolidation
and
optimization	 	 	Acquisition
and
integration	 	 	 
Asset
dispositions,
severance
and other	 	 	Debt /
investment
related
charges	 	 	 	 	Adjusted
Continuing
Operations	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Sales	 	$	286,168	 	 				 	$	(1,604	) 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 		 	$	284,564	 	
Cost of sales	 	 	196,982	 	 				 	 	1,846	 	 	 	(3,786	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	195,042	 	
Gross profit (loss)	 	 	89,186	 	 	 		 	 	 	(3,450	) 	 	 	3,786	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	89,522	 	
Gross margin	 	 	31%	 	 				 	 	-1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	31%	 	
Operating expenses:	 				 				 				 				 				 				 				 				 				 		 				
Selling, general and administrative	 	 	35,064	 	 				 	 	-	 	 	 	(6,222	) 	 	 	(1,735	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	27,107	 	
SG&A as a % of sales	 	 	12%	 	 				 	 	0%	 	 	 	-2%	 	 	 	-1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	10%	 	
Research, development and engineering	 	 	12,227	 	 				 	 	-	 	 	 	(137	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	12,090	 	
RD&E as a % of sales	 	 	4%	 	 				 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	4%	 	
Other operating expenses	 	 	6,069	 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	(2,979	) 	 	 	(2,267	) 	 	 	(823	) 	 	 	-	 	 		 	 	-	 	
Total operating expenses	 	 	53,360	 	 				 	 	-	 	 	 	(6,359	) 	 	 	(1,735	) 	 	 	(2,979	) 	 	 	(2,267	) 	 	 	(823	) 	 	 	-	 	 		 	 	39,197	 	
Operating income (loss)	 	 	35,826	 	 				 	 	(3,450	) 	 	 	10,145	 	 	 	1,735	 	 	 	2,979	 	 	 	2,267	 	 	 	823	 	 	 	-	 	 		 	 	50,325	 	
Operating margin	 	 	13%	 	 				 	 	-1%	 	 	 	4%	 	 	 	1%	 	 	 	1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 		 	 	18%	 	
Interest expense	 	 	15,808	 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(778	) 	 		 	 	15,030	 	
Loss (gain) on cost and equity investments, net	 	 	(1,906	) 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	1,906	 	 		 	 	-	 	
Other loss, net	 	 	2,490	 	 				 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	2,490	 	
Income (loss) before taxes	 	 	19,434	 	 				 	 	(3,450	) 	 	 	10,145	 	 	 	1,735	 	 	 	2,979	 	 	 	2,267	 	 	 	823	 	 	 	(1,128	) 	 		 	 	32,805	 	
Provision (benefit) for income taxes	 	 	(448	) 	 				 	 	(1,208	) 	 	 	3,042	 	 	 	607	 	 	 	349	 	 	 	1,161	 	 	 	277	 	 	 	(395	) 	 		 	 	3,385	 	
Effective tax rate	 	 	-2%	 	 				 	 	35%	 	 	 	30%	 	 	 	35%	 	 	 	12%	 	 	 	51%	 	 	 	34%	 	 	 	35%	 	 		 	 	10%	 	
Net income (loss)	 	$	19,882	 	 				 	$	(2,242	) 	 	$	7,103	 	 	$	1,128	 	 	$	2,630	 	 	$	1,106	 	 	$	546	 	 	$	(733	) 	 		 	$	29,420	 	

Diluted earnings (loss) per share	 	$	0.62	 	 				 	$	(0.07	) 	 	$	0.22	 	 	$	0.04	 	 	$	0.08	 	 	$	0.03	 	 	$	0.02	 	 	$	(0.02	) 	 		 	$	0.91	 	
												
Weighted average shares - Diluted	 	 	32,173	 	 				 	 	32,173	 	 	 	32,173	 	 	 	32,173	 	 	 	32,173	 	 	 	32,173	 	 	 	32,173	 	 	 	32,173	 	 		 	 	32,173	 	
 
Page 18 of 39

			
	  	STATEMENT OF CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
2017 Q4	

 	 	GAAP	 	 	 	 	Adjustments	 	 	 	 	Non-GAAP	 	
 	 	Continuing
Operations	 	 	 	 	LSA
adjustment	 	 	Amortization
of intangibles	 	 	IP related
litigation	 	 	Strategic
reorganization
and alignment	 	 	Consolidation
and
optimization	 	 	Acquisition
and
integration	 	 	Asset
dispositions,
severance
and other	 	 	Debt /
investment
related
charges	 	 	Tax
Adjustment	 	 	 	 	Adjusted
Continuing
Operations	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Sales	 	$	302,260	 	 		 	$	(1,568	) 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 		 	$	300,692	 	
Cost of sales	 	 	208,639	 	 		 	 	2,043	 	 	 	(3,901	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	206,781	 	
Gross profit (loss)	 	 	93,621	 	 		 	 	(3,611	) 	 	 	3,901	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	93,911	 	
Gross margin	 	 	31%	 	 		 	 	-1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	31%	 	
Operating expenses:	 				 		 				 				 				 				 				 				 				 				 				 		 				
Selling, general and administrative	 	 	38,069	 	 		 	 	-	 	 	 	(6,156	) 	 	 	(1,348	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	30,565	 	
SG&A as a % of sales	 	 	13%	 	 		 	 	0%	 	 	 	-2%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	10%	 	
Research, development and engineering	 	 	13,746	 	 		 	 	-	 	 	 	(136	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	13,610	 	
RD&E as a % of sales	 	 	5%	 	 		 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	5%	 	
Other operating expenses	 	 	11,948	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	(5,891	) 	 	 	(4,880	) 	 	 	(813	) 	 	 	(364	) 	 	 	-	 	 	 	-	 	 		 	 	-	 	
Total operating expenses	 	 	63,763	 	 		 	 	-	 	 	 	(6,292	) 	 	 	(1,348	) 	 	 	(5,891	) 	 	 	(4,880	) 	 	 	(813	) 	 	 	(364	) 	 	 	-	 	 	 	-	 	 		 	 	44,175	 	
Operating income (loss)	 	 	29,858	 	 		 	 	(3,611	) 	 	 	10,193	 	 	 	1,348	 	 	 	5,891	 	 	 	4,880	 	 	 	813	 	 	 	364	 	 	 	-	 	 	 	-	 	 		 	 	49,736	 	
Operating margin	 	 	10%	 	 		 	 	-1%	 	 	 	3%	 	 	 	0%	 	 	 	2%	 	 	 	2%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	17%	 	
Interest expense	 	 	14,739	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(252	) 	 	 	-	 	 		 	 	14,487	 	
Loss (gain) on cost and equity investments, net	 	 	(1,354	) 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	1,354	 	 	 	-	 	 		 	 	-	 	
Other loss, net	 	 	199	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	199	 	
Income (loss) before taxes	 	 	16,274	 	 		 	 	(3,611	) 	 	 	10,193	 	 	 	1,348	 	 	 	5,891	 	 	 	4,880	 	 	 	813	 	 	 	364	 	 	 	(1,102	) 	 	 	-	 	 		 	 	35,050	 	
Provision (benefit) for income taxes	 	 	(38,424	) 	 		 	 	(1,264	) 	 	 	3,076	 	 	 	472	 	 	 	2,062	 	 	 	1,147	 	 	 	(113	) 	 	 	8	 	 	 	(386	) 	 	 	39,806	 	 		 	 	6,384	 	
Effective tax rate	 	 	-236%	 	 		 	 	35%	 	 	 	30%	 	 	 	35%	 	 	 	0%	 	 	 	24%	 	 	 	-14%	 	 	 	2%	 	 	 	35%	 	 	 	 	 	 		 	 	18%	 	
Net income (loss)	 	$	54,698	 	 		 	$	(2,347	) 	 	$	7,117	 	 	$	876	 	 	$	3,829	 	 	$	3,733	 	 	$	926	 	 	$	356	 	 	$	(716	) 	 	$	(39,806	) 	 		 	$	28,666	 	

Diluted earnings (loss) per share	 	$	1.69	 	 		 	$	(0.07	) 	 	$	0.22	 	 	$	0.03	 	 	$	0.12	 	 	$	0.12	 	 	$	0.03	 	 	$	0.01	 	 	$	(0.02	) 	 	$	(1.23	) 	 		 	$	0.89	 	
														
Weighted average shares - Diluted	 	 	32,383	 	 		 	 	32,383	 	 	 	32,383	 	 	 	32,383	 	 	 	32,383	 	 	 	32,383	 	 	 	32,383	 	 	 	32,383	 	 	 	32,383	 	 	 	32,383	 	 		 	 	32,383	 	
 
Page 19 of 39

			
	  	STATEMENT OF CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
2017 FISCAL YEAR	

 	 	GAAP	 	 	 	 	Adjustments	 	 	 	 	Non-GAAP	 	
 	 	Continuing
Operations	 	 	 	 	LSA
adjustment	 	 	Amortization
of intangibles	 	 	IP related
litigation	 	 	Strategic
reorganization
and alignment	 	 	Consolidation
and
optimization	 	 	Acquisition
and
integration	 	 	Asset
dispositions,
severance
and other	 	 	Debt /
investment
related
charges	 	 	Tax
Adjustment	 	 	 	 	Adjusted
Continuing
Operations	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Sales	 	$	1,136,080	 	 		 	$	(5,326	) 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 		 	$	1,130,754	 	
Cost of sales	 	 	782,070	 	 		 	 	7,646	 	 	 	(15,183	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	774,533	 	
Gross profit (loss)	 	 	354,010	 	 		 	 	(12,972	) 	 	 	15,183	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	356,221	 	
Gross margin	 	 	31%	 	 		 	 	-1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	32%	 	
Operating expenses:	 				 		 				 				 				 				 				 				 				 				 				 		 				
Selling, general and administrative	 	 	143,073	 	 		 	 	-	 	 	 	(24,840	) 	 	 	(4,375	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	113,858	 	
SG&A as a % of sales	 	 	13%	 	 		 	 	0%	 	 	 	-2%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	10%	 	
Research, development and engineering	 	 	48,850	 	 		 	 	-	 	 	 	(545	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	48,305	 	
RD&E as a % of sales	 	 	4%	 	 		 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	4%	 	
Other operating expenses	 	 	36,438	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	(5,891	) 	 	 	(12,803	) 	 	 	(10,870	) 	 	 	(6,874	) 	 	 	-	 	 	 	-	 	 		 	 	-	 	
Total operating expenses	 	 	228,361	 	 		 	 	-	 	 	 	(25,385	) 	 	 	(4,375	) 	 	 	(5,891	) 	 	 	(12,803	) 	 	 	(10,870	) 	 	 	(6,874	) 	 	 	-	 	 	 	-	 	 		 	 	162,163	 	
Operating income (loss)	 	 	125,649	 	 		 	 	(12,972	) 	 	 	40,568	 	 	 	4,375	 	 	 	5,891	 	 	 	12,803	 	 	 	10,870	 	 	 	6,874	 	 	 	-	 	 	 	-	 	 		 	 	194,058	 	
Operating margin	 	 	11%	 	 		 	 	-1%	 	 	 	4%	 	 	 	0%	 	 	 	1%	 	 	 	1%	 	 	 	1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 		 	 	17%	 	
Interest expense	 	 	63,972	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(3,524	) 	 	 	-	 	 		 	 	60,448	 	
Loss (gain) on cost and equity investments, net	 	 	1,565	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(1,565	) 	 	 	-	 	 		 	 	-	 	
Other loss, net	 	 	10,853	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	10,853	 	
Income (loss) before taxes	 	 	49,259	 	 		 	 	(12,972	) 	 	 	40,568	 	 	 	4,375	 	 	 	5,891	 	 	 	12,803	 	 	 	10,870	 	 	 	6,874	 	 	 	5,089	 	 	 	-	 	 		 	 	122,757	 	
Provision (benefit) for income taxes	 	 	(37,828	) 	 		 	 	(4,541	) 	 	 	12,246	 	 	 	1,531	 	 	 	2,062	 	 	 	2,545	 	 	 	3,668	 	 	 	2,374	 	 	 	1,781	 	 	 	39,806	 	 		 	 	23,644	 	
Effective tax rate	 	 	-77%	 	 		 	 	35%	 	 	 	30%	 	 	 	35%	 	 	 	0%	 	 	 	20%	 	 	 	34%	 	 	 	35%	 	 	 	35%	 	 	 	 	 	 		 	 	19%	 	
Net income (loss)	 	$	87,087	 	 		 	$	(8,431	) 	 	$	28,322	 	 	$	2,844	 	 	$	3,829	 	 	$	10,258	 	 	$	7,202	 	 	$	4,500	 	 	$	3,308	 	 	$	(39,806	) 	 		 	$	99,113	 	

Diluted earnings (loss) per share	 	$	2.72	 	 		 	$	(0.26	) 	 	$	0.88	 	 	$	0.09	 	 	$	0.12	 	 	$	0.32	 	 	$	0.22	 	 	$	0.14	 	 	$	0.10	 	 	$	(1.24	) 	 		 	$	3.09	 	
														
Weighted average shares - Diluted	 	 	32,056	 	 		 	 	32,056	 	 	 	32,056	 	 	 	32,056	 	 	 	32,056	 	 	 	32,056	 	 	 	32,056	 	 	 	32,056	 	 	 	32,056	 	 	 	32,056	 	 		 	 	32,056	 	
 
Page 20 of 39

			
	  	STATEMENT OF CONTINUING OPERATIONS
GAAP TO NON-GAAP RECONCILIATION
2018 Q1	

 	 	GAAP	 	 	 	 	Adjustments	 	 	 	 	Non-GAAP	 	
 	 	Continuing
Operations	 	 	 	 	LSA
adjustment	 	 	Amortization
of intangibles	 	 	IP related
litigation	 	 	Strategic
reorganization
and alignment	 	 	 
Manufacturing
alignment to
support growth	 	 	Consolidation
and
optimization	 	 	Asset
dispositions,
severance
and other	 	 	Debt /
investment
related
charges	 	 	Tax
Adjustment	 	 	 	 	Adjusted
Continuing
Operations	 	
 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Sales	 	$	292,426	 	 		 	$	(695	) 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 	$	-	 	 		 	$	291,731	 	
Cost of sales	 	 	208,894	 	 		 	 	2,141	 	 	 	(3,716	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	207,319	 	
Gross profit (loss)	 	 	83,532	 	 		 	 	(2,836	) 	 	 	3,716	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	84,412	 	
Gross margin	 	 	29%	 	 		 	 	-1%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	29%	 	
Operating expenses:	 				 		 				 				 				 				 				 				 				 				 				 		 				
Selling, general and administrative	 	 	36,429	 	 		 	 	-	 	 	 	(6,898	) 	 	 	(321	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	29,210	 	
SG&A as a % of sales	 	 	12%	 	 		 	 	0%	 	 	 	-2%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	10%	 	
Research, development and engineering	 	 	13,276	 	 		 	 	-	 	 	 	(39	) 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	13,237	 	
RD&E as a % of sales	 	 	5%	 	 		 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	5%	 	
Other operating expenses	 	 	3,784	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	(2,054	) 	 	 	(513	) 	 	 	(575	) 	 	 	(642	) 	 	 	-	 	 	 	-	 	 		 	 	-	 	
Total operating expenses	 	 	53,489	 	 		 	 	-	 	 	 	(6,937	) 	 	 	(321	) 	 	 	(2,054	) 	 	 	(513	) 	 	 	(575	) 	 	 	(642	) 	 	 	-	 	 	 	-	 	 		 	 	42,447	 	
Operating income (loss)	 	 	30,043	 	 		 	 	(2,836	) 	 	 	10,653	 	 	 	321	 	 	 	2,054	 	 	 	513	 	 	 	575	 	 	 	642	 	 	 	-	 	 	 	-	 	 		 	 	41,965	 	
Operating margin	 	 	10%	 	 		 	 	-1%	 	 	 	4%	 	 	 	0%	 	 	 	1%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 	 	0%	 	 		 	 	14%	 	
Interest expense	 	 	15,595	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	(1,057	) 	 	 	-	 	 		 	 	14,538	 	
Loss (gain) on cost and equity investments, net	 	 	(4,970	) 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	4,970	 	 	 	-	 	 		 	 	-	 	
Other loss, net	 	 	960	 	 		 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 	 	-	 	 		 	 	960	 	
Income (loss) before taxes	 	 	18,458	 	 		 	 	(2,836	) 	 	 	10,653	 	 	 	321	 	 	 	2,054	 	 	 	513	 	 	 	575	 	 	 	642	 	 	 	(3,913	) 	 	 	-	 	 		 	 	26,467	 	
Provision (benefit) for income taxes	 	 	5,374	 	 		 	 	(596	) 	 	 	2,256	 	 	 	67	 	 	 	427	 	 	 	144	 	 	 	120	 	 	 	172	 	 	 	(822	) 	 	 	(1,094	) 	 		 	 	6,048	 	
Effective tax rate	 	 	29%	 	 		 	 	21%	 	 	 	21%	 	 	 	21%	 	 	 	0%	 	 	 	0%	 	 	 	21%	 	 	 	27%	 	 	 	21%	 	 	 	 	 	 		 	 	23%	 	
Net income (loss)	 	$	13,084	 	 		 	$	(2,240	) 	 	$	8,397	 	 	$	254	 	 	$	1,627	 	 	$	369	 	 	$	455	 	 	$	470	 	 	$	(3,091	) 	 	$	1,094	 	 		 	$	20,419	 	

Diluted earnings (loss) per share	 	$	0.40	 	 		 	$	(0.07	) 	 	$	0.26	 	 	$	0.01	 	 	$	0.05	 	 	$	0.01	 	 	$	0.01	 	 	$	0.01	 	 	$	(0.10	) 	 	$	0.03	 	 		 	$	0.63	 	
														
Weighted average shares - Diluted	 	 	32,423	 	 		 	 	32,423	 	 	 	32,423	 	 	 	32,423	 	 	 	32,423	 	 	 	32,423	 	 	 	32,423	 	 	 	32,423	 	 	 	32,423	 	 	 	32,423	 	 		 	 	32,423	 	
 
Page 21 of 39

			
	  	SALES
GAAP TO NON-GAAP RECONCILIATION
2017 Q1	

 	  	GAAP	 	 	 	 	NON-GAAP	
						
 	  	(a)	 	LESS:	 	 	 	 	 	 	Adjusted	
 	  	Total	 	Discontinued	 	Continuing	 	 	 	 	Continuing	
 	  	Operations	 	Operations	 	Operations	 	Adjustments	 	 	Operations	
 	  	 	 	 	 	 	 	 	 	 	 	
Medical	  				 				 				 				 				
Cardio & Vascular	  	  $	125,108	 	 	  $	1,624	 	 	  $	123,484	 	 	  $	2 	    (b)  	 	  $	    123,486	 	
Cardiac & Neuromodulation	  	 	103,813	 	 	 	58	 	 	 	103,755	 	 	 	(2)	    (b)  	 	 	103,753	  	
Advanced Surgical, Orthopedics & Portable Medical	  	 	105,146	 	 	 	76,995	 	 	 	28,151	 	 	 	(1,480)	    (b)  	 	 	26,671	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total Medical	  	 	334,067	 	 	 	78,677	 	 	 	255,390	 	 	 	(1,480)	 	 	 	253,910	 	
Non-Medical	  	 	11,346	 	 	 	-    	 	 	 	11,346	 	 	 	-      	 	 	 	11,346	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total sales	  	  $	    345,413	  	 	  $	    78,677	  	 	  $	    266,736	  	 	  $	    (1,480)	 	 	  $	265,256	 	

(a)	As previously reported in SEC filings prior to July 2018.	
(b)	Net impact of LSA agreement.	
 
Page 22 of 39

			
	  	SALES
GAAP TO NON-GAAP RECONCILIATION
2017 Q2	

																					
 	  	GAAP	 	 	 	 	NON-GAAP	
						
 	  	(a)	 	LESS:	 	 	 	 	 	 	Adjusted	
 	  	Total	 	Discontinued	 	Continuing	 	 	 	 	Continuing	
 	  	Operations	 	Operations	 	Operations	 	Adjustments	 	 	Operations	
 	  	 	 	 	 	 	 	 	 	 	 	
Medical	  				 				 				 				 				
Cardio & Vascular	  	  $	    132,231	 	 	  $	1,513	 	 	  $	130,718	 	 	  $	(1)	  (b)  	 	  $	130,717	 	
Cardiac & Neuromodulation	  	 	106,185	 	 	 	12	 	 	 	106,173	 	 	 	-    	  (b)  	 	 	106,173	 	
Advanced Surgical, Orthopedics & Portable Medical	  	 	108,560	 	 	 	80,278	 	 	 	28,282	 	 	 	(673)	   (b)  	 	 	27,609	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total Medical	  	 	346,976	 	 	 	81,803	 	 	 	265,173	 	 	 	(674)	 	 	 	264,499	 	
Non-Medical	  	 	15,743	 	 	 	-    	 	 	 	15,743	 	 	 	-    	 	 	 	15,743	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total sales	  	  $	362,719	  	 	  $	      81,803	  	 	  $	    280,916	  	 	  $	    (674)	 	 	  $	    280,242	  	

(a)	As previously reported in SEC filings prior to July 2018.	
(b)	Net impact of LSA agreement.	
 
Page 23 of 39

			
	  	SALES
GAAP TO NON-GAAP RECONCILIATION
2017 Q3	

 	  	GAAP	 	 	 	 	NON-GAAP	
						
 	  	(a)	 	LESS:	 	 	 	 	 	 	Adjusted	
 	  	Total	 	Discontinued	 	Continuing	 	 	 	 	Continuing	
 	  	Operations	 	Operations	 	Operations	 	Adjustments	 	 	Operations	
 	  	 	 	 	 	 	 	 	 	 	 	
Medical	  				 				 				 				 				
Cardio & Vascular	  	  $	138,982	 	 	  $	1,270	 	 	  $	137,712	 	 	  $	(16)	   (b)  	 	  $	    137,696	  	
Cardiac & Neuromodulation	  	 	101,616	  	 	 	4	 	 	 	101,612	 	 	 	-    	   (b)  	 	 	101,612	 	
Advanced Surgical, Orthopedics & Portable Medical	  	 	107,581	 	 	 	75,866	  	 	 	31,715	 	 	 	(1,588)	   (b)  	 	 	30,127	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total Medical	  	 	348,179	 	 	 	77,140	 	 	 	    271,039	  	 	 	(1,604)	 	 	 	269,435	 	
Non-Medical	  	 	15,129	 	 	 	-    	 	 	 	15,129	 	 	 	-    	 	 	 	15,129	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total sales	  	  $	    363,308	 	 	  $	      77,140	 	 	  $	286,168	 	 	  $	          (1,604)	 	 	  $	284,564	 	

(a)	As previously reported in SEC filings prior to July 2018.	
(b)	Net impact of LSA agreement.	
 
Page 24 of 39

			
	  	SALES
GAAP TO NON-GAAP RECONCILIATION
2017 Q4	

																					
 	  	GAAP	 	 	 	 	NON-GAAP	
						
 	  	(a)	 	LESS:	 	 	 	 	 	 	Adjusted	
 	  	Total	 	Discontinued	 	Continuing	 	 	 	 	Continuing	
 	  	Operations	 	Operations	 	Operations	 	Adjustments	 	 	Operations	
 	  	 	 	 	 	 	 	 	 	 	 	
Medical	  				 				 				 				 				
Cardio & Vascular	  	  $	140,473	 	 	  $	1,556	 	 	  $	138,917	  	 	$	(12)	   (b)  	 	$	138,905	 	
Cardiac & Neuromodulation	  	 	116,735	 	 	 	-      	 	 	 	116,735	 	 	 	-      	   (b)  	 	 	116,735	 	
Advanced Surgical, Orthopedics & Portable Medical	  	 	118,523	  	 	 	86,665	  	 	 	31,858	 	 	 	(1,556)	   (b)  	 	 	30,302	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total Medical	  	 	375,731	 	 	 	88,221	 	 	 	287,510	 	 	 	(1,568)	 	 	 	    285,942	 	
Non-Medical	  	 	14,750	 	 	 	-      	 	 	 	14,750	 	 	 	-      	 	 	 	14,750	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total sales	  	  $	    390,481	 	 	  $	        88,221	 	 	  $	    302,260	 	 	  $	      (1,568)	 	 	$	300,692	  	

(a)	As previously reported in SEC filings prior to July 2018.	
(b)	Net impact of LSA agreement.	
 
Page 25 of 39

			
	  	SALES
GAAP TO NON-GAAP RECONCILIATION
2017 FISCAL YEAR	

 	  	GAAP	 	 	 	 	NON-GAAP	
						
 	  	(a)	 	LESS:	 	 	 	 	 	 	Adjusted	
 	  	Total	 	Discontinued	 	Continuing	 	 	 	 	Continuing	
 	  	Operations	 	Operations	 	Operations	 	Adjustments	 	 	Operations	
 	  	 	 	 	 	 	 	 	 	 	 	
Medical	  				 				 				 				 				
Cardio & Vascular	  	  $	536,794	 	 	  $	5,963	 	 	  $	530,831	 	 	$	(27)	   (b)  	 	$	530,804	 	
Cardiac & Neuromodulation	  	 	428,349	 	 	 	74	 	 	 	428,275	 	 	 	(2)	   (b)  	 	 	428,273	 	
Advanced Surgical, Orthopedics & Portable Medical	  	 	439,810	 	 	 	    319,804	  	 	 	120,006	 	 	 	(5,297)	   (b)  	 	 	114,709	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total Medical	  	 	1,404,953	  	 	 	325,841	 	 	 	1,079,112	 	 	 	(5,326)	 	 	 	1,073,786	 	
Non-Medical	  	 	56,968	 	 	 	-    	 	 	 	56,968	  	 	 	-    	 	 	 	56,968	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total sales	  	  $	    1,461,921	 	 	  $	325,841	 	 	  $	    1,136,080	 	 	$	        (5,326)	 	 	$	  1,130,754	  	

(a)	As previously reported in SEC filings prior to July 2018.	
(b)	Net impact of LSA agreement.	
 
Page 26 of 39

			
	  	SALES
GAAP TO NON-GAAP RECONCILIATION
2018 Q1	

																					
 	  	GAAP	 	 	 	 	NON-GAAP	
						
 	  	(a)	 	LESS:	 	 	 	 	 	 	Adjusted	
 	  	Total	 	Discontinued	 	Continuing	 	 	 	 	Continuing	
 	  	Operations	 	Operations	 	Operations	 	Adjustments	 	 	Operations	
 	  	 	 	 	 	 	 	 	 	 	 	
Medical	  				 				 				 				 				
Cardio & Vascular	  	$	138,348	 	 	$	1,485	 	 	$	136,863	 	 	$	(11)	   (b)  	 	$	136,852	 	
Cardiac & Neuromodulation	  	 	108,910	 	 	 	-    	 	 	 	108,910	 	 	 	-    	   (b)  	 	 	108,910	 	
Advanced Surgical, Orthopedics & Portable Medical	  	 	121,775	 	 	 	87,834	 	 	 	33,941	 	 	 	(684)	   (b)  	 	 	33,257	 	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total Medical	  	 	369,033	 	 	 	89,319	 	 	 	279,714	  	 	 	(695)	 	 	 	279,019	 	
Non-Medical	  	 	12,712	 	 	 	-    	 	 	 	12,712	 	 	 	-    	 	 	 	12,712	  	
	  	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	
Total sales	  	$	381,745	  	 	$	89,319	  	 	$	292,426	 	 	$	(695)	 	 	$	291,731	 	

(a)	As previously reported in SEC filings prior to July 2018.	
(b)	Net impact of LSA agreement.	
 
Page 27 of 39

			
	  	NET INCOME
GAAP TO NON-GAAP RECONCILIATION
2017 Q1	

													
 	  	(a)	 	LESS:	 	 	
 	  	Total	 	Discontinued	 	Continuing	
Net Income (Loss) Reconciliation *	  	Operations	 	Operations	 	Operations	
	  				 				 				
Net income (loss) (GAAP)	  	  $	(4,339	) 	 	  $	(7,287	) 	 	  $	2,948	 	
Adjustments:	  				 				 				
Amortization of intangibles	  	 	7,746	 	 	 	728	 	 	 	7,018	 	
Depreciation on held for sale assets	  	 	-  	 	 	 	-    	 	 	 	-    	 	
IP related litigation (SG&A)	  	 	245	 	 	 	-    	 	 	 	245	 	
Strategic reorganization and alignment (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Manufacturing alignment to support growth (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses (OOE)	  	 	1,899	 	 	 	32	 	 	 	1,867	 	
Acquisition and integration expenses (OOE)	  	 	3,133	 	 	 	-    	 	 	 	3,133	 	
Asset dispositions, severance and other (OOE)	  	 	2,957	 	 	 	29	 	 	 	2,928	 	
Loss on cost/equity method investments	  	 	259	 	 	 	-    	 	 	 	259	 	
Loss on extinguishment of debt	  	 	1,013	 	 	 	-    	 	 	 	1,013	 	
LSA adjustments	  	 	-    	 	 	 	2,051	 	 	 	(2,051	) 	
Tax adjustments	  	 	-    	 	 	 	-    	 	 	 	-    	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted net income (loss) (Non-GAAP)	  	  $	      12,913	  	 	  $	(4,447	) 	 	  $	      17,360	 	

Diluted earnings (loss) per share	  	  $	0.41	 	 	  $	(0.14	) 	 	  $	0.55	 	
				
Weighted average shares outstanding - Diluted	  	 	31,685	 	 	 	      31,685	 	 	 	31,685	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
*	Amounts shown are net of tax.	
 
Page 28 of 39

			
	  	NET INCOME
GAAP TO NON-GAAP RECONCILIATION
2017 Q2	

 	  	(a)	 	LESS:	 	 	
 	  	Total	 	Discontinued	 	Continuing	
Net Income (Loss) Reconciliation *	  	Operations	 	Operations	 	Operations	
	  				 				 				
Net income (loss) (GAAP)	  	  $	2,990	 	 	  $	(6,569	) 	 	  $	9,559	 	
Adjustments:	  				 				 				
Amortization of intangibles	  	 	7,815	 	 	 	731	 	 	 	7,084	 	
Depreciation on held for sale assets	  	 	-    	 	 	 	-    	 	 	 	-    	 	
IP related litigation (SG&A)	  	 	595	 	 	 	-    	 	 	 	595	 	
Strategic reorganization and alignment (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Manufacturing alignment to support growth (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses (OOE)	  	 	2,093	 	 	 	65	 	 	 	2,028	 	
Acquisition and integration expenses (OOE)	  	 	2,037	 	 	 	-    	 	 	 	2,037	 	
Asset dispositions, severance and other (OOE)	  	 	727	 	 	 	57	 	 	 	670	 	
Loss on cost/equity method investments	  	 	2,877	 	 	 	-    	 	 	 	2,877	 	
Loss on extinguishment of debt	  	 	608	 	 	 	-    	 	 	 	608	 	
LSA adjustments	  	 	-    	 	 	 	1,791	 	 	 	(1,791	) 	
Tax adjustments	  	 	-    	 	 	 	-    	 	 	 	-    	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted net income (loss) (Non-GAAP)	  	  $	      19,742	  	 	  $	(3,925	) 	 	  $	      23,667	 	

Diluted earnings (loss) per share	  	  $	0.62	 	 	  $	(0.12	) 	 	  $	0.74	 	
				
Weighted average shares outstanding - Diluted	  	 	31,982	 	 	 	      31,982	 	 	 	31,982	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
*	Amounts shown are net of tax.	
 
Page 29 of 39

			
	  	NET INCOME
GAAP TO NON-GAAP RECONCILIATION
2017 Q3	

 	  	(a)	 	LESS:	 	 	
 	  	Total	 	  Discontinued  	 	Continuing	
Net Income (Loss) Reconciliation *	  	  Operations  	 	Operations	 	  Operations  	
	  				 				 				
Net income (loss) (GAAP)	  	  $	13,690	 	 	  $	(6,192	) 	 	  $	      19,882	 	
Adjustments:	  				 				 				
Amortization of intangibles	  	 	7,840	 	 	 	737	 	 	 	7,103	 	
Depreciation on held for sale assets	  	 	-    	 	 	 	-    	 	 	 	-    	 	
IP related litigation (SG&A)	  	 	1,128	 	 	 	-    	 	 	 	1,128	 	
Strategic reorganization and alignment (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Manufacturing alignment to support growth (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses (OOE)	  	 	2,737	 	 	 	107	 	 	 	2,630	 	
Acquisition and integration expenses (OOE)	  	 	1,106	 	 	 	-    	 	 	 	1,106	 	
Asset dispositions, severance and other (OOE)	  	 	563	 	 	 	17	 	 	 	546	 	
Gain on cost/equity method investments	  	 	(1,239	) 	 	 	-    	 	 	 	(1,239	) 	
Loss on extinguishment of debt	  	 	506	 	 	 	-    	 	 	 	506	 	
LSA adjustments	  	 	-    	 	 	 	2,242	 	 	 	(2,242	) 	
Tax adjustments	  	 	-    	 	 	 	-    	 	 	 	-    	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted net income (loss) (Non-GAAP)	  	  $	      26,331	 	 	  $	(3,089	) 	 	  $	29,420	 	

Diluted earnings (loss) per share	  	  $	0.82	 	 	  $	(0.10	) 	 	  $	0.91	 	
				
Weighted average shares outstanding - Diluted	  	 	32,173	 	 	 	      32,173	 	 	 	32,173	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
*	Amounts shown are net of tax.	
 
Page 30 of 39

			
	  	NET INCOME
GAAP TO NON-GAAP RECONCILIATION
2017 Q4	

 	  	(a)	 	LESS:	 	 	
 	  	Total	 	Discontinued	 	Continuing	
Net Income (Loss) Reconciliation *	  	Operations	 	Operations	 	Operations	
	  				 				 				
Net income (loss) (GAAP)	  	  $	54,338	 	 	  $	(360	) 	 	  $	      54,698	 	
Adjustments:	  				 				 				
Amortization of intangibles	  	 	7,854	 	 	 	737	 	 	 	7,117	 	
Depreciation on held for sale assets	  	 	-    	 	 	 	-    	 	 	 	-    	 	
IP related litigation (SG&A)	  	 	876	 	 	 	-    	 	 	 	876	 	
Strategic reorganization and alignment (OOE)	  	 	3,829	 	 	 	-    	 	 	 	3,829	 	
Manufacturing alignment to support growth (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses (OOE)	  	 	3,886	 	 	 	153	 	 	 	3,733	 	
Acquisition and integration expenses (OOE)	  	 	926	 	 	 	-    	 	 	 	926	 	
Asset dispositions, severance and other (OOE)	  	 	475	 	 	 	119	 	 	 	356	 	
Gain on cost/equity method investments	  	 	(880	) 	 	 	-    	 	 	 	(880	) 	
Loss on extinguishment of debt	  	 	164	 	 	 	-    	 	 	 	164	 	
LSA adjustments	  	 	-    	 	 	 	2,347	 	 	 	(2,347	) 	
Tax adjustments	  	 	(40,281	) 	 	 	(475	) 	 	 	(39,806	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted net income (loss) (Non-GAAP)	  	  $	      31,187	 	 	  $	2,521	 	 	  $	28,666	 	

Diluted earnings (loss) per share	  	  $	0.96	 	 	  $	0.08	 	 	  $	0.89	 	
				
Weighted average shares outstanding - Diluted	  	 	32,383	 	 	 	      32,383	 	 	 	32,383	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
*	Amounts shown are net of tax.	
 
Page 31 of 39

			
	  	NET INCOME
GAAP TO NON-GAAP RECONCILIATION
2017 FISCAL YEAR	

Net Income (Loss) Reconciliation *	  	(a)
Total
  Operations  	 	LESS:
  Discontinued  
Operations	 	Continuing
  Operations  	
 	  	 	 	 	 	 	
Net income (loss) (GAAP)	  	  $	66,679	 	 	  $	(20,408	) 	 	  $	87,087	 	
Adjustments:	  				 				 				
Amortization of intangibles	  	 	31,255	 	 	 	2,933	 	 	 	28,322	 	
Depreciation on held for sale assets	  	 	-    	 	 	 	-    	 	 	 	-    	 	
IP related litigation (SG&A)	  	 	2,844	 	 	 	-    	 	 	 	2,844	 	
Strategic reorganization and alignment (OOE)	  	 	3,829	 	 	 	-    	 	 	 	3,829	 	
Manufacturing alignment to support growth (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses (OOE)	  	 	10,615	 	 	 	357	 	 	 	10,258	 	
Acquisition and integration expenses (OOE)	  	 	7,202	 	 	 	-    	 	 	 	7,202	 	
Asset dispositions, severance and other (OOE)	  	 	4,722	 	 	 	222	 	 	 	4,500	 	
Loss on cost/equity method investments	  	 	1,017	 	 	 	-    	 	 	 	1,017	 	
Loss on extinguishment of debt	  	 	2,291	 	 	 	-    	 	 	 	2,291	 	
LSA adjustments	  	 	-    	 	 	 	8,431	 	 	 	(8,431	) 	
Tax adjustments	  	 	(40,281	) 	 	 	(475	) 	 	 	(39,806	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted net income (loss) (Non-GAAP)	  	  $	90,173	 	 	  $	(8,940	) 	 	  $	99,113	 	

Diluted earnings (loss) per share	  	  $	2.81	 	 	  $	(0.28	) 	 	  $	3.09	 	
				
Weighted average shares outstanding - Diluted	  	 	32,056	 	 	 	32,056	 	 	 	32,056	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
*	Amounts shown are net of tax.	
 
Page 32 of 39

			
	  	NET INCOME
GAAP TO NON-GAAP RECONCILIATION
2018 Q1	

Net Income (Loss) Reconciliation *	  	(a)
Total
  Operations  	 	LESS:
  Discontinued  
Operations	 	Continuing
  Operations  	
 	  	 	 	 	 	 	
Net income (loss) (GAAP)	  	  $	8,118	 	 	  $	(4,966	) 	 	  $	13,084	 	
Adjustments:	  				 				 				
Amortization of intangibles	  	 	9,304	 	 	 	907	 	 	 	8,397	 	
Depreciation on held for sale assets	  	 	-    	 	 	 	-    	 	 	 	-    	 	
IP related litigation (SG&A)	  	 	254	 	 	 	-    	 	 	 	254	 	
Strategic reorganization and alignment (OOE)	  	 	2,779	 	 	 	1,152	 	 	 	1,627	 	
Manufacturing alignment to support growth (OOE)	  	 	369	 	 	 	-    	 	 	 	369	 	
Consolidation and optimization expenses (OOE)	  	 	473	 	 	 	18	 	 	 	455	 	
Acquisition and integration expenses (OOE)	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Asset dispositions, severance and other (OOE)	  	 	489	 	 	 	19	 	 	 	470	 	
Gain on cost/equity method investments	  	 	(3,926	) 	 	 	-    	 	 	 	(3,926	) 	
Loss on extinguishment of debt	  	 	835	 	 	 	-    	 	 	 	835	 	
LSA adjustments	  	 	-    	 	 	 	2,240	 	 	 	(2,240	) 	
Tax adjustments	  	 	1,021	 	 	 	(73	) 	 	 	1,094	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted net income (loss) (Non-GAAP)	  	  $	19,716	 	 	  $	(703	) 	 	  $	20,419	 	

Diluted earnings (loss) per share	  	  $	0.61	 	 	  $	(0.02	) 	 	  $	0.63	 	
				
Weighted average shares outstanding - Diluted	  	 	32,423	 	 	 	32,423	 	 	 	32,423	 	
 
(a)	As previously reported in SEC filings prior to July 2018.	
 
*	Amounts shown are net of tax.	
 
Page 33 of 39

			
	  	EBITDA
GAAP TO NON-GAAP RECONCILIATION
2017 Q1	

EBITDA and Adjusted EBITDA Reconciliation	  	(a)
Total
  Operations  	 	LESS:
  Discontinued  
Operations	 	Continuing
  Operations  	
 	  	 	 	 	 	 	
Net income (loss) (GAAP)  	  	  $	(4,339	) 	 	  $	(7,287	) 	 	  $	2,948	 	
Adjustments:	  				 				 				
Interest expense	  	 	28,893	 	 	 	10,526	 	 	 	18,367	 	
Provision (benefit) for income taxes	  	 	144	 	 	 	(645	) 	 	 	789	 	
Depreciation	  	 	13,628	 	 	 	4,258	 	 	 	9,370	 	
Amortization	  	 	10,978	 	 	 	895	 	 	 	10,083	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
EBITDA	  	 	49,304	 	 	 	7,747	 	 	 	41,557	 	
IP related litigation	  	 	377	 	 	 	-    	 	 	 	377	 	
Stock-based compensation (excluding OOE)	  	 	2,406	 	 	 	233	 	 	 	2,173	 	
Strategic reorganization and alignment	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Manufacturing alignment to support growth	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses	  	 	2,395	 	 	 	48	 	 	 	2,347	 	
Acquisition and integration expenses	  	 	4,820	 	 	 	-    	 	 	 	4,820	 	
Asset dispositions, severance and other	  	 	4,556	 	 	 	29	 	 	 	4,527	 	
Non-cash loss on cost/equity method investments	  	 	398	 	 	 	-    	 	 	 	398	 	
LSA adjustments	  	 	-    	 	 	 	3,155	 	 	 	(3,155	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted EBITDA (Non-GAAP)	  	  $	    64,256	 	 	  $	    11,212	 	 	  $	    53,044	 	

(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 34 of 39

			
	  	EBITDA
GAAP TO NON-GAAP RECONCILIATION
2017 Q2	

EBITDA and Adjusted EBITDA Reconciliation	  	(a)
Total
  Operations  	  	LESS:
  Discontinued  
Operations	 	Continuing
  Operations  	
 	  	 	  	 	 	 	
Net income (loss) (GAAP)	  	  $	2,990	 	  	  $	(6,569	) 	 	  $	9,559	 	
Adjustments:	  				  				 				
Interest expense	  	 	25,647	 	  	 	10,589	 	 	 	15,058	 	
Provision for income taxes	  	 	1,126	 	  	 	871	 	 	 	255	 	
Depreciation	  	 	13,813	 	  	 	4,455	 	 	 	9,358	 	
Amortization	  	 	11,046	 	  	 	899	 	 	 	10,147	 	
	  	 	 	 	  	 	 	 	 	 	 	 	
EBITDA	  	 	54,622	 	  	 	10,245	 	 	 	44,377	 	
IP related litigation	  	 	915	 	  	 	-    	 	 	 	915	 	
Stock-based compensation (excluding OOE)	  	 	3,251	 	  	 	349	 	 	 	2,902	 	
Strategic reorganization and alignment	  	 	-    	 	  	 	-    	 	 	 	-    	 	
Manufacturing alignment to support growth	  	 	-    	 	  	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses	  	 	2,832	 	  	 	103	 	 	 	2,729	 	
Acquisition and integration expenses	  	 	2,970	 	  	 	-    	 	 	 	2,970	 	
Asset dispositions, severance and other	  	 	1,118	 	  	 	90	 	 	 	1,028	 	
Non-cash loss on cost/equity method investments	  	 	4,427	 	  	 	-    	 	 	 	4,427	 	
LSA adjustments	  	 	-    	 	  	 	2,756	 	 	 	(2,756	) 	
	  	 	 	 	  	 	 	 	 	 	 	 	
Adjusted EBITDA (Non-GAAP)	  	  $	    70,135	 	  	  $	    13,543	 	 	  $	    56,592	 	

(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 35 of 39

			
	  	EBITDA
GAAP TO NON-GAAP RECONCILIATION
2017 Q3	

EBITDA and Adjusted EBITDA Reconciliation	  	(a)
Total
  Operations  	 	LESS:
  Discontinued  
Operations	 	Continuing
  Operations  	
 	  	 	 	 	 	 	
Net income (loss) (GAAP)	  	  $	13,690	 	 	  $	(6,192	) 	 	  $	19,882	 	
Adjustments:	  				 				 				
Interest expense	  	 	26,485	 	 	 	10,677	 	 	 	15,808	 	
Benefit for income taxes	  	 	(1,700	) 	 	 	(1,252	) 	 	 	(448	) 	
Depreciation	  	 	14,068	 	 	 	4,534	 	 	 	9,534	 	
Amortization	  	 	11,051	 	 	 	906	 	 	 	10,145	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
EBITDA	  	 	63,594	 	 	 	8,673	 	 	 	54,921	 	
IP related litigation	  	 	1,735	 	 	 	-    	 	 	 	1,735	 	
Stock-based compensation (excluding OOE)	  	 	2,149	 	 	 	108	 	 	 	2,041	 	
Strategic reorganization and alignment	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Manufacturing alignment to support growth	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses	  	 	3,143	 	 	 	164	 	 	 	2,979	 	
Acquisition and integration expenses	  	 	2,267	 	 	 	-    	 	 	 	2,267	 	
Asset dispositions, severance and other	  	 	854	 	 	 	31	 	 	 	823	 	
Non-cash gain on cost/equity method investments	  	 	(992	) 	 	 	-    	 	 	 	(992	) 	
LSA adjustments	  	 	-    	 	 	 	3,450	 	 	 	(3,450	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted EBITDA (Non-GAAP)	  	  $	    72,750	 	 	  $	    12,426	 	 	  $	    60,324	 	

(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 36 of 39

			
	  	EBITDA
GAAP TO NON-GAAP RECONCILIATION
2017 Q4

													
EBITDA and Adjusted EBITDA Reconciliation	  	(a)
Total
  Operations  	 	LESS:
Discontinued
Operations	 	Continuing
  Operations  	
 	  	 	 	 	 	 	
Net income (loss) (GAAP)	  	  $	54,338	 	 	  $	(360	) 	 	  $	54,698	 	
Adjustments:	  				 				 				
Interest expense	  	 	25,435	 	 	 	10,696	 	 	 	14,739	 	
Benefit for income taxes	  	 	(44,422	) 	 	 	(5,998	) 	 	 	(38,424	) 	
Depreciation	  	 	14,575	 	 	 	4,760	 	 	 	9,815	 	
Amortization	  	 	11,099	 	 	 	906	 	 	 	10,193	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
EBITDA	  	 	61,025	 	 	 	10,004	 	 	 	51,021	 	
IP related litigation	  	 	1,348	 	 	 	-    	 	 	 	1,348	 	
Stock-based compensation (excluding OOE)	  	 	4,618	 	 	 	451	 	 	 	4,167	 	
Strategic reorganization and alignment	  	 	5,891	 	 	 	-    	 	 	 	5,891	 	
Manufacturing alignment to support growth	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses	  	 	5,111	 	 	 	231	 	 	 	4,880	 	
Acquisition and integration expenses	  	 	813	 	 	 	-    	 	 	 	813	 	
Asset dispositions, severance and other	  	 	522	 	 	 	158	 	 	 	364	 	
Non-cash gain on cost/equity method investments	  	 	(868	) 	 	 	-    	 	 	 	(868	) 	
LSA adjustments	  	 	-    	 	 	 	3,611	 	 	 	(3,611	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted EBITDA (Non-GAAP)	  	  $	        78,460	 	 	  $	        14,455	 	 	  $	        64,005	 	

(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 37 of 39

			
	  	EBITDA
GAAP TO NON-GAAP RECONCILIATION
2017 FISCAL YEAR	

EBITDA and Adjusted EBITDA Reconciliation	  	(a)
Total
  Operations  	 	LESS:
Discontinued
Operations	 	Continuing
  Operations  	
 	  	 	 	 	 	 	
Net income (loss) (GAAP)	  	  $	66,679	 	 	  $	(20,408	) 	 	  $	87,087	 	
Adjustments:	  				 				 				
Interest expense	  	 	106,460	 	 	 	42,488	 	 	 	63,972	 	
Benefit for income taxes	  	 	(44,852	) 	 	 	(7,024	) 	 	 	(37,828	) 	
Depreciation	  	 	56,084	 	 	 	18,007	 	 	 	38,077	 	
Amortization	  	 	44,174	 	 	 	3,606	 	 	 	40,568	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
EBITDA	  	 	228,545	 	 	 	36,669	 	 	 	191,876	 	
IP related litigation	  	 	4,375	 	 	 	-    	 	 	 	4,375	 	
Stock-based compensation (excluding OOE)	  	 	12,424	 	 	 	1,141	 	 	 	11,283	 	
Strategic reorganization and alignment	  	 	5,891	 	 	 	-    	 	 	 	5,891	 	
Manufacturing alignment to support growth	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Consolidation and optimization expenses	  	 	13,349	 	 	 	546	 	 	 	12,803	 	
Acquisition and integration expenses	  	 	10,870	 	 	 	-    	 	 	 	10,870	 	
Asset dispositions, severance and other	  	 	7,182	 	 	 	308	 	 	 	6,874	 	
Non-cash loss on cost/equity method investments	  	 	2,965	 	 	 	-    	 	 	 	2,965	 	
LSA adjustments	  	 	-    	 	 	 	12,972	 	 	 	(12,972	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted EBITDA (Non-GAAP)	  	  $	    285,601	 	 	  $	      51,636	 	 	  $	    233,965	 	

(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 38 of 39

			
	  	EBITDA
GAAP TO NON-GAAP RECONCILIATION
2018 Q1	

EBITDA and Adjusted EBITDA Reconciliation	  	(a)
Total
Operations	 	LESS:
Discontinued
Operations	 	Continuing
Operations	
 	  	 	 	 	 	 	
Net income (loss) (GAAP)	  	  $	8,118	 	 	  $	(4,966	) 	 	  $	13,084	 	
Adjustments:	  				 				 				
Interest expense	  	 	26,445	 	 	 	10,850	 	 	 	15,595	 	
Provision (benefit) for income taxes	  	 	4,091	 	 	 	(1,283	) 	 	 	5,374	 	
Depreciation	  	 	14,621	 	 	 	4,658	 	 	 	9,963	 	
Amortization	  	 	11,713	 	 	 	1,060	 	 	 	10,653	 	
	  	 	 	 	 	 	 	 	 	 	 	 	
EBITDA	  	 	64,988	 	 	 	10,319	 	 	 	54,669	 	
IP related litigation	  	 	321	 	 	 	-    	 	 	 	321	 	
Stock-based compensation (excluding OOE)	  	 	3,218	 	 	 	239	 	 	 	2,979	 	
Strategic reorganization and alignment	  	 	3,492	 	 	 	1,438	 	 	 	2,054	 	
Manufacturing alignment to support growth	  	 	513	 	 	 	-    	 	 	 	513	 	
Consolidation and optimization expenses	  	 	605	 	 	 	30	 	 	 	575	 	
Acquisition and integration expenses	  	 	-    	 	 	 	-    	 	 	 	-    	 	
Asset dispositions, severance and other	  	 	667	 	 	 	25	 	 	 	642	 	
Non-cash gain on cost/equity method investments	  	 	(4,970	) 	 	 	-    	 	 	 	(4,970	) 	
LSA adjustments	  	 	-    	 	 	 	2,836	 	 	 	(2,836	) 	
	  	 	 	 	 	 	 	 	 	 	 	 	
Adjusted EBITDA (Non-GAAP)	  	  $	        68,834	 	 	  $	        14,887	 	 	  $	        53,947	 	

(a)	As previously reported in SEC filings prior to July 2018.	
 
Page 39 of 39